Recent Updates
Recently added Catalysts

NovoLog

Phase 3

Type 2 Diabetes Treated With Insulin | Small molecule | Metabolic |Novo Nordisk A/S|Last Updated: Mar 19, 2024

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLED
Total Trials1
Total Enrollment137
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT04460326Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes MellitusPHASE3 COMPLETED 137Dec 7, 2020May 27, 2023Mar 19, 20241 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Postprandial Glucose Control
3 days

Percent of time spent in the glycemic target range of 100-180 mg/dL in the 4 hour postprandial period will be assessed using a continuous glucose monitoring (CGM) system.

Secondary Endpoints
Glycemic Control While Hospitalized
3 days
Percent of Time Spent in Glycemic Range of 70-140 mg/dL
3 days
Percent of Time Spent With Hypoglycemia During Hospitalization
3 days
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Group 1 insulin glargine and NovologACTIVE_COMPARATORGroup 1 will receive daily basal insulin glargine with a scheduled bolus of meal insulin Novolog. Meal Novolog will be dosed at the time the subject starts to eat. If the premeal blood glucose (BG) is ≥ 150 mg/dL, additional Novolog will be administered based off the correctional scale at the same time as the prandial insulin. The dose of Novolog will be administered by the floor nurse as per usual standard of care.
Group 2 insulin glargine and FiaspEXPERIMENTALGroup 2 will receive basal insulin glargine as dosed in Group 1. Meal insulin Fiasp dosing will be calculated the same way as Novolog dosing. If the premeal BG is ≥ 150 mg/dL, additional Fiasp will be administered based off the correctional scale at the same time as the prandial insulin.
Interventions
NameTypeDescription
Insulin glargineDRUGInsulin glargine doses will be determined by calculating the total daily dose (TDD) of insulin and providing 50% of the TDD as follows: start at 0.5 units/kg/day and subtract 0.1 unit/kg/day for 70+ yrs of age, renal insufficiency, pancreatic deficiency and add 0.1 unit/kg/day if hemoglobin A1c in \>10%
NovoLogDRUGNovolog will be administered with each meal if premeal glucose is ≥ 150 mg/dL and at bedtime if glucose is ≥ 200 mg/dL by calculating an individualized insulin sensitivity factor for each subject per the following formula: 1500/total daily dose of insulin = sensitivity factor.
Insulin FiaspDRUGFiasp will be administered with each meal if premeal glucose is ≥ 150 mg/dL and at bedtime if glucose is ≥ 200 mg/dL by calculating an individualized insulin sensitivity factor for each subject per the following formula: 1500/total daily dose of insulin = sensitivity factor.
Standard carbohydrate dietOTHERStandard carbohydrate diet as per usual hospital care (75g with each meal)
Unlock Study Design Details
Eligibility Criteria
Age Range21 Years — 80 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion criteria 1. English-speaking 2. Males and female adult subjects admitted to Boston Medical Center to a medical or surgical floor. 3. Consultation by the Inpatient Diabetes Service at Boston Medical Center is required prior to consent. 4. Age ≥ 21 and \<= 80 years. 5. Diagnosed with type 2...

Countries:United States
Unlock Eligibility Criteria